REMARKS

Clean set of claim 103 is included in this response for the convenience of the Examiner. No changes have been made to claim 103 by the current response. Also included is a corrected marked-up version of claim 103. The correction addresses an issue of indication of deleted words "isolated" and "are" in claim 103 inadvertently omitted in the marked-up version of the amendments made to claim 103 by the amendment filed January 25, 2002.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **532732000200**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 16, 2002

Respectfully submitted,

By: _____

Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125

CORRECTED VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claim 103 has been amended as follows:

103. (Amended) An isolated, enriched or purified immunogenic composition comprising:

[(a)] one or more [isolated] autologous target carcinoma or lymphoma cells [hepatocellular carcinoma, lymphoma or colorectal carcinoma] which [are] have been irradiated and treated [with IFN-γ, TNF-α, or both] in vitro [and which express one or more CD28 or 4-1-BB] wherein said target carcinoma or lymphoma cells express one or more primary or costimulatory T cell activation molecules at a level higher than [said one or more CD28 or 4-1BB] the amount of primary or costimulatory T cell activation molecules expressed from [hepatocellular carcinoma, lymphoma or colorectal carcinoma] carcinoma or lymphoma cells without treatment in a patient mammal;

[(b) one or more antibodies comprising one or more binding sites for said one or more CD28 or 4-1BB molecules on the surface of T cells in said patient mammal, wherein said one or more antibodies further comprise one or more antigen binding sites for one or more gp55 antigens on the surface of said one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells, wherein one or more of said one or more antibodies are attached to one or more of said one or more target hepatocellular carcinoma, lymphoma or colorectal carcinoma cells at said one or more gp55 antigens.]

one or more antibodies wherein said antibodies further bind to an antigenic binding site on the surface of said one or more target carcinoma or lymphoma cells;

one or more primary or costimulatory T cell activation molecules on the surface of T cells in said patient mammal; and

a bridge molecule binding said antibodies and said primary or costimulatory T cell activation molecules on the surface of T cells of said patient mammal.